Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aimovig in Temporomandibular Disorder
NCT04884763Phase 2Completed
- Sponsor
- Indiana University
- Start
- Nov 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erenumab in temporomandibular joint disorders (TMD), sponsored by Indiana University. Started Nov 2021; status: completed.
02
Drugs
erenumab
03
Conditions
temporomandibular joint disorders (TMD)
Beyond the preview
Go deeper on NCT04884763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884763.